Corimmun
Drug development company focused on therapeutics and diagnostics for heart and vascular diseases.
Launch date
Market cap
-
Enterprise valuation
AUD51—76m (Dealroom.co estimates Oct 2010.)
Company register number HRB 16738 (Neuss)
Neuss Nordrhein-Westfalen (HQ & founding location)
Financials
Estimates*
| EUR | 2007 | 2008 | 2010 | 2011 | 2012 | 2015 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | <1m | <1m |
| Profit | (<1m) | (1.9m) | (2.4m) | (1.9m) | (<1m) | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€680k | Seed | ||
| N/A | €5.0m | Series A | |
€7.5m | Series B | ||
N/A | Acquisition | ||
| Total Funding | AUD22.3m | ||